Wiviott Stephen D, Cannon Christopher P, Morrow David A, Murphy Sabina A, Gibson C Michael, McCabe Carolyn H, Sabatine Marc S, Rifai Nader, Giugliano Robert P, DiBattiste Peter M, Demopoulos Laura A, Antman Elliott M, Braunwald Eugene
Cardiovascular Division, Brigham and Women's Hospital, 75 Francis St, Boston, Mass 02115, USA.
Circulation. 2004 Feb 10;109(5):580-6. doi: 10.1161/01.CIR.0000109491.66226.26.
Diagnosis of coronary artery disease in women is more difficult because of lower specificity of symptoms and diagnostic accuracy of noninvasive testing. We sought to examine the relationship between gender and cardiac biomarkers in patients with unstable angina (UA)/non-ST-segment elevation myocardial infarction (NSTEMI).
In the TACTICS-TIMI 18, OPUS-TIMI 16, and TIMI 11 studies, baseline samples were analyzed in the Thrombolysis In Myocardial Infarction (TIMI) biomarker core laboratory. We examined the relationship between gender and elevated biomarkers. Of 1865 patients from TACTICS-TIMI 18, 34% were women. Fewer women had elevated creatine kinase-MB or troponins, whereas more had elevated high-sensitivity C-reactive protein or brain natriuretic peptide. Presence of ST-segment deviation and TIMI risk scores were not significantly different. This pattern was confirmed in TIMI 11 and OPUS-TIMI 16. The prognostic value of the markers in TACTICS-TIMI 18 was similar in women and men. When a multimarker approach was examined, a greater proportion of high-risk women were identified. Marker-positive patients of both genders had improved outcome with an invasive strategy; however, marker-negative women appeared to have improved outcomes with a conservative strategy.
In patients with UA/NSTEMI, there was a different pattern of presenting biomarkers. Men were more likely to have elevated creatine kinase-MB and troponins, whereas women were more likely to have elevated C-reactive protein and brain natriuretic peptide. This suggests that a multimarker approach may aid the initial risk assessment of UA/NSTEMI, especially in women. Further research is necessary to elucidate whether gender-related pathophysiological differences exist in presentation with acute coronary syndromes.
由于症状特异性较低以及无创检测的诊断准确性较低,女性冠状动脉疾病的诊断更为困难。我们试图研究不稳定型心绞痛(UA)/非ST段抬高型心肌梗死(NSTEMI)患者的性别与心脏生物标志物之间的关系。
在TACTICS-TIMI 18、OPUS-TIMI 16和TIMI 11研究中,对心肌梗死溶栓治疗(TIMI)生物标志物核心实验室的基线样本进行了分析。我们研究了性别与生物标志物升高之间的关系。在TACTICS-TIMI 18研究的1865例患者中,34%为女性。肌酸激酶同工酶或肌钙蛋白升高的女性较少,而高敏C反应蛋白或脑钠肽升高的女性较多。ST段偏移的存在和TIMI风险评分无显著差异。这种模式在TIMI 11和OPUS-TIMI 16研究中得到了证实。TACTICS-TIMI 18研究中这些标志物的预后价值在男性和女性中相似。当采用多标志物方法时,识别出的高危女性比例更高。两种性别的标志物阳性患者采用侵入性策略时预后改善;然而,标志物阴性的女性采用保守策略时似乎预后改善。
在UA/NSTEMI患者中,生物标志物的表现模式不同。男性肌酸激酶同工酶和肌钙蛋白升高的可能性更大,而女性C反应蛋白和脑钠肽升高的可能性更大。这表明多标志物方法可能有助于UA/NSTEMI的初始风险评估,尤其是在女性中。有必要进一步研究以阐明急性冠状动脉综合征的表现中是否存在与性别相关的病理生理差异。